{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:40:45Z","timestamp":1786621245419,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014455","name":"University of Tennessee, Knoxville","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014455","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.nucmedbio.2026.109655","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:21:55Z","timestamp":1782400915000},"page":"109655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Enhanced pre-therapy dosimetry for SSTR PET: A head-to-head preclinical assessment of [89Zr]Zr-DFO-TOC and [89Zr]Zr-DFO-TATE"],"prefix":"10.1016","volume":"158-159","author":[{"given":"Alexis M.","family":"Sanwick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine N.","family":"Haugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin R.","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivis F.","family":"Chaple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.nucmedbio.2026.109655_bb0005","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.nucmedbio.2026.109655_bb0010","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109655_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ph13030038","article-title":"[68Ga] Ga-DOTA-TOC: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging","volume":"13","author":"Hennrich","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109655_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/ph12030114","article-title":"Lutathera((R)): the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"10.1016\/j.nucmedbio.2026.109655_bb0025","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2967\/jnumed.122.264183","article-title":"Choice is good at times: the emergence of [64Cu] Cu-DOTATATE\u2013based somatostatin receptor imaging in the era of [68Ga] Ga-DOTATATE","volume":"63","author":"Jha","year":"2022","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.nucmedbio.2026.109655_bb0030","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2967\/jnumed.121.262305","article-title":"Dosimetry in radiopharmaceutical therapy","volume":"63","author":"O\u2019Donoghue","year":"2022","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.nucmedbio.2026.109655_bb0035","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1021\/acs.bioconjchem.5c00369","article-title":"Design, synthesis, and preclinical evaluation of 89Zr\/177Lu-FAPI-Tz: a potential theranostic pair targeting fibroblast activation protein","volume":"36","author":"Ma","year":"2025","journal-title":"Bioconjug Chem"},{"issue":"5","key":"10.1016\/j.nucmedbio.2026.109655_bb0040","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s00259-023-06575-9","article-title":"Theranostic role of 89Zr- and 177Lu-labeled aflibercept in breast cancer","volume":"51","author":"Yang","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109655_bb0045","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s41181-024-00320-9","article-title":"[(89)Zr]Zr-DFO-TOC: a novel radiopharmaceutical for PET imaging of somatostatin receptor positive neuroendocrine tumors","volume":"9","author":"Sanwick","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2026.109655_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nucmedbio.2017.03.004","article-title":"Production of Zr-89 using sputtered yttrium coin targets (89)Zr using sputtered yttrium coin targets","volume":"50","author":"Queern","year":"2017","journal-title":"Nucl Med Biol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109655_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1258\/0023677021911731","article-title":"Use of allometry in predicting anatomical and physiological parameters of mammals","volume":"36","author":"Lindstedt","year":"2002","journal-title":"Lab Anim"},{"issue":"5","key":"10.1016\/j.nucmedbio.2026.109655_bb0060","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/en.2009-1313","article-title":"In vivo molecular imaging of somatostatin receptors in pancreatic islet cells and neuroendocrine tumors by miniaturized confocal laser-scanning fluorescence microscopy","volume":"151","author":"Fottner","year":"2010","journal-title":"Endocrinology"},{"issue":"8","key":"10.1016\/j.nucmedbio.2026.109655_bb0065","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3109\/1061186X.2011.558089","article-title":"Investigation of cancer cell lines for peptide receptor-targeted drug development","volume":"19","author":"Sun","year":"2011","journal-title":"J Drug Target"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109655_bb0070","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1038\/s41598-022-10139-6","article-title":"(89)Zr-PET imaging to predict tumor uptake of (177)Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma","volume":"12","author":"Giesen","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109655_bb0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s41181-022-00181-0","article-title":"Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC\/HPLC analysis, demonstrated by [(177Lu)]Lu-PSMA","volume":"7","author":"Hooijman","year":"2022","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"11","key":"10.1016\/j.nucmedbio.2026.109655_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111624","article-title":"Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice","volume":"9","author":"Soto-Montenegro","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.nucmedbio.2026.109655_bb0090","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.addr.2008.04.005","article-title":"Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins","volume":"60","author":"Akizawa","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"10.1016\/j.nucmedbio.2026.109655_bb0095","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1021\/acs.bioconjchem.1c00109","article-title":"Imaging somatostatin positive tumors with Tyr3-octreotate\/octreotide conjugated to desferrioxamine B squaramide radiolabeled with either zirconium-89 or gallium-68","volume":"32","author":"Noor","year":"2021","journal-title":"Bioconjug Chem"},{"issue":"4","key":"10.1016\/j.nucmedbio.2026.109655_bb0100","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.nucmedbio.2013.01.007","article-title":"Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas","volume":"40","author":"Bhattacharyya","year":"2013","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2026.109655_bb0105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.radphyschem.2013.11.003","article-title":"Effective dose to immuno-PET patients due to metastable impurities in cyclotron produced zirconium-89","volume":"104","author":"Alfuraih","year":"2014","journal-title":"Radiat Phys Chem"},{"issue":"6","key":"10.1016\/j.nucmedbio.2026.109655_bb0110","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s11307-016-0951-z","article-title":"[(89)Zr]Trastuzumab: evaluation of radiation dosimetry, safety, and optimal imaging parameters in women with HER2-positive breast cancer","volume":"18","author":"Laforest","year":"2016","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109655_bb0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2967\/jnumed.117.194555","article-title":"Pharmacokinetics, biodistribution, and radiation dosimetry for 89Zr-trastuzumab in patients with esophagogastric cancer","volume":"59","author":"O\u2019Donoghue","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109655_bb0120","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fonc.2022.882541","article-title":"PET imaging of acidic tumor environment with 89Zr-labeled pHLIP probes","volume":"12","author":"Bauer","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.nucmedbio.2026.109655_bb0125","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2967\/jnumed.113.120600","article-title":"Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors","volume":"54","author":"Sandstr\u00f6m","year":"2013","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109655_bb0130","first-page":"19","article-title":"Preclinical study of (68)Ga-DOTATOC: biodistribution assessment in Syrian rats and evaluation of absorbed dose in human organs","volume":"4","author":"Naderi","year":"2016","journal-title":"Asia Ocean J Nucl Med Biol"},{"issue":"8","key":"10.1016\/j.nucmedbio.2026.109655_bb0135","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2967\/jnumed.111.101469","article-title":"Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study","volume":"53","author":"Pfeifer","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109655_bb0140","series-title":"ICRP publication 80: radiation dose to patients from radiopharmaceuticals","author":"Icrp","year":"2015"},{"issue":"7","key":"10.1016\/j.nucmedbio.2026.109655_bb0145","first-page":"1148","article-title":"Pharmacokinetics and biodistribution of (86)Y-trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI","volume":"44","author":"Palm","year":"2003","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.nucmedbio.2026.109655_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/ph15091085","article-title":"Comparison of the anti-tumour activity of the somatostatin receptor (SST) antagonist [(177)Lu]Lu-satoreotide tetraxetan and the agonist [(177)Lu]Lu-DOTA-TATE in mice bearing AR42J SST(2)-positive tumours","volume":"15","author":"Plas","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.nucmedbio.2026.109655_bb0155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13550-015-0099-x","article-title":"Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE","volume":"5","author":"Schottelius","year":"2015","journal-title":"EJNMMI Res"},{"issue":"4","key":"10.1016\/j.nucmedbio.2026.109655_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195802","article-title":"The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model","volume":"13","author":"Rylova","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109655_bb0165","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s00259-020-05002-7","article-title":"Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical (89)Zr-immuno-PET","volume":"48","author":"Chomet","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"20","key":"10.1016\/j.nucmedbio.2026.109655_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/molecules30204129","article-title":"The evaluation of (1R,4R,7R,10R)-\u03b1,\u03b1\u2019,\u03b1\u2033,\u03b1\u2034-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTMA) as a chelator for Zirconium-89","volume":"30","author":"Pandya","year":"2025","journal-title":"Molecules"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:25:41Z","timestamp":1786620341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805126000545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"alternative-id":["S0969805126000545"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109655","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced pre-therapy dosimetry for SSTR PET: A head-to-head preclinical assessment of [89Zr]Zr-DFO-TOC and [89Zr]Zr-DFO-TATE","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109655"}}